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Introduction
Intratumoral hypoxia has been shown to be a prognostic
parameter in diverse studies [1]. Electrode measurements
of oxygen tension have thus far served as the gold
standard for its determination. The disadvantage of this
method is its inability to discriminate between different cell
types and areas of different cell viability [2].
Hypoxia-inducible factor 1 is a heterodimeric DNA-binding
complex, of which the β subunit is responsible for its trans-
location into the nucleus and the α subunit for its oxygen
sensitivity. Under normoxic conditions the hypoxia-inducible
factor 1 alpha (hif-1α) protein is degraded within minutes,
whereas under hypoxic conditions it is stabilized and up-
regulated [3]. hif-1α is a transcription factor for target
genes, involved in cell adaptation to stress parameters such
as hypoxia. These genes are involved mainly in the
modulation of erythropoesis, angiogenesis and metabolism.
A spatial coexpression of hif-1α and the nitroimidazole
EF5, the levels of which are selectively lowered only in
viable hypoxic cells, was recently reported [4]. Further-
DFS = disease-free survival; DMFS = distant metastasis-free survival; 5-FU = 5-fluorouracil; hif-1α = hypoxia-inducible factor 1 alpha; OS = overall survival.
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Abstract
Background: Hypoxia-inducible factor 1 alpha (hif-1α) furnishes
tumor cells with the means of adapting to stress parameters
like tumor hypoxia and promotes critical steps in tumor
progression and aggressiveness. We investigated the role of
hif-1α expression in patients with node-positive breast cancer.
Methods: Tumor samples from 77 patients were available for
immunohistochemistry. The impact of hif-1α immunoreactivity
on survival endpoints was determined by univariate and
multivariate analyses, and correlations to clinicopathological
characteristics were determined by cross-tabulations.
Results: hif-1α was expressed in 56% (n = 43/77) of the
patients. Its expression correlated with progesterone receptor
negativity (P = 0.002). The Kaplan–Meier curves revealed
significantly shorter distant metastasis-free survival (DMFS)
(P = 0.04, log-rank) and disease-free survival (DFS) (P = 0.04,
log-rank) in patients with increased hif-1α expression. The
difference in overall survival (OS) did not attain statistical
significance (5-year OS, 66% without hif-1α expression and
55% with hif-1α expression; P = 0.21). The multivariate analysis
failed to reveal an independent prognostic value for hif-1α
expression in the whole patient group. The only significant
parameter for all endpoints was the T stage (T3/T4 versus
T1/T2: DMFS, relative risk = 3.16, P = 0.01; DFS, relative risk =
2.57, P = 0.03; OS, relative risk = 3.03, P = 0.03). Restricting
the univariate and multivariate analyses to T1/T2 tumors, hif-1α
expression was a significant parameter for DFS and DMFS.
Conclusions: hif-1α is expressed in the majority of patients
with node-positive breast cancer. It can serve as a prognostic
marker for an unfavorable outcome in those with T1/T2 tumors
and positive axillary lymph nodes.
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more, a correlation has been found to exist between hif-1α
immunoreactivity and tumor hypoxia as defined using the
Eppendorf oxygen electrode [5]. Both findings indicate
that hif-1α might serve as a potential marker for intra-
tumoral hypoxia.
In one study hif-1α has been reported to be involved in
breast carcinogenesis [6]. hif-1α expression in normal
breast tissue was compared with that in different
pathological stages of breast cancer. hif-1α was detected
neither in normal tissue nor in hyperplastic ductal lesions,
but it was expressed at progressively increasing levels in
higher stage tumors. Since the overexpression of hif-1α
has been reported for 13 of 19 common tumor types [7], it
may play an important role in tumorigenesis generally.
Data relating to the clinical impact of hif-1α expression in
breast cancer are scarce and controversial in node-
positive cases [8,9]. The aim of the present study was to
investigate the consequence of its expression on the
clinical outcome of patients with node-positive breast
cancer, who carry a high risk of relapse.
In this series hif-1α is expressed in the majority of patients
with node-positive breast cancer. We can support the use
of hif-1α expression as a prognostic parameter in node-
positive patients, although its value was restricted to
patients with T1/T2 tumors.
Materials and methods
Patients with non-disseminated breast cancer and a high
risk for relapse were eligible for this study. ‘High risk’ was
defined by the presence of lymph node metastasis and
extracapsular spreading of the tumor in one or more
axillary lymph nodes. Between August 1988 and June
1998 this information was available in 81 patients with a
median age of 57 years (mean age, 56 years; age range,
26–87 years) who met these criteria according to our
database. Paraffin-embedded tissue samples from 77
patients were obtained.
The clinical characteristics of the patient cohort are
summarized in Table 1. The ductal breast carcinomas
were graded I, II and III based on the Scarff–Bloom and
Richardson grading system modified by Elston and Ellis.
All patients had segmental mastectomy with axillary
lymph node dissection (level I, level II, or ± level III) or
modified radical mastectomy. The median number of
lymph nodes examined was 15 (mean, 17; range,
6–37), of which a median number of five (mean, seven;
range, 1–27) were positive. The total number of lymph
nodes could not be precisely defined in seven patients
owing to conglomeration. Since the pathological reports
noted many lymph nodes to be metastatic, these
patients were included in the subgroup with >3 positive
lymph nodes.
Systemic adjuvant treatment was administered to all but
three patients, who refused it. The treatment consisted of
tamoxifen (n = 59), toremifen (n = 3) or chemotherapy
(n = 64). The chemotherapeutic regimens used were:
adriamycin or epirubicin and cyclophosphamide in 13
cases; cyclophosphamide, methotrexate and 5-fluorouracil
(5-FU) in 16 cases; and adriamycin or epirubicin and
cyclophosphamide followed by cyclophosphamide, metho-
trexate and 5-FU in 28 cases. The following treatment
combinations were given to single patients: cyclo-
phosphamide, methotrexate, 5-FU, vincristine and pred-
nisone; adriamycin or epirubicin and cyclophosphamide/
docetaxel or paclitaxel and cyclophosphamide; and
docetaxel or paclitaxel and adriamycin or epirubicin/
cyclophosphamide, methotrexate and 5-FU. 5-FU, adria-
mycin or epirubicin and cyclophosphamide was given to
four patients.
All patients underwent radiotherapy. In 46 of these patients
radiotherapy was local only, whereas in the other 35
patients the ipsilateral subclavian region, the infraclavicular
chest wall and level III of the axilla were also irradiated. A
monocentric four-field technique was used to cover the
locoregional target volume. The median total dose was
50.4 Gy for the lymphatics. Irradiation of the chest wall or
breast was performed using single doses of 1.8 or 2 Gy,
which summed to a total dose of 48.6–64.8 Gy (median,
50.4 Gy).
The mean follow-up time was 36 months (range,
12–95 months).
Immunohistochemistry
After approval of the regional ethical committee, paraffin-
embedded tissues from 77 patients were collected and
processed for immunohistochemistry. Sections (3 µm
thick) were transferred to gelatinized microslides and were
air-dried overnight at 37ºC. They were dewaxed in xylene
(three changes), rehydrated in a graded series of
decreasing ethanol concentration and then rinsed in Tris-
buffered saline (50 mM Tris–HCl [pH 7.4] containing
100 mM sodium chloride).
Immunostaining for hif-1α was performed according to the
Catalyzed Signal Amplification System (Dako, Carpinteria,
CA, USA), which utilizes a streptavidin–biotin–horseradish
peroxidase complex. The slides were initially immersed in
target retrieval solution (Dako) at 97ºC for 15 min and
were then treated in accordance with the manufacturer’s
instructions. They were exposed to a monoclonal antibody
H1a67 (Novus Biologicals, Littleton, CO, USA) diluted
1:5000 for 30 min at ambient temperature. The biotinyl
tyramide amplification reagent was diluted 1:10 in protein
blocking solution (Dako). In the case of mouse anti-CD31,
the antibody reaction is preceded by treatment with
trypsin (0.2 mg/ml in TBS/CaCl2 buffer; Difco Laboratories,R193
Detroit, MI, USA) for 10 min at 37°C. After the blockage of
nonspecific binding by immersion in TBS containing 1%
casein (SIGMA 8654) for 10 min, sections were incuba-
ted with the first antibody diluted in TBS: mouse anti-
CD31, 1:20 (JC/70A, M-0823; Dako, Glostrup, Denmark)
(for details, see [10]).
The reaction product was visualized by exposing sections
to 3,3-diaminobenzidine for 1 min at ambient temperature.
Nuclei were lightly counterstained with hematoxylin.
Sections were then mounted in Aquatex® (Merck,
Darmstadt, Germany). Tissue samples incubated with
nonimmune serum or with the antibody diluent (Dako)
served as negative controls. Sections from a previous
study on mesopharynx carcinoma [10] were employed as
a positive control. The quality (number, intensity and
pattern) of every staining procedure for hypoxia-inducible
factor 1α has been comparatively evaluated using consecu-
tive control sections.
Tumor-cell immunoreactivity was scored according to both
the extent of nuclear staining (relative number of hif-1α-
positive cells) and the intensity of the reaction: –, not
detected; (+), <1% positive cells; +, 1–10% weakly to
moderately stained cells; ++, 1–10% intensively stained
cells or 10–50% weakly stained cells; +++, 10–50%
positive cells with moderate to marked staining; ++++,
>50% positive cells.
For the statistical analysis, the six grades of staining were
reduced to three grades: negative, [0/(+)]; I, moderate
[+/++]; and II, intense [+++/++++]. The assessment was
performed in a blinded fashion by an experienced
investigator (VD).
Statistics
The bivariate analysis involving hif-1α expression and
clinicopathological covariables was performed using chi-
square tests, the level of significance being 5%.
The following endpoints were examined for survival
analyses: distant metastasis-free survival (DMFS), disease-
free survival (DFS) and overall survival (OS). Survival time
was calculated from the time of surgery until death (for
OS) or, if the patient was still alive, until the last follow-up
visit (for DMFS and for DFS). Local, regional or distant
tumor progression was taken into account as adverse
events for DFS, whereas for DMFS only distant tumor
progression was considered. Death from any cause was
considered for OS. Local progression-free survival, DFS
and OS curves were plotted according to the Kaplan–
Meier method, the log-rank test being used to determine
the significance of differences between these. Parameters
with P < 0.1 in the univariate analysis were included in the
multivariate Cox regression analysis (enter limit, 0.1;
remove limit, 0.05).
Results
All patients
Thirty-four patients (44%) qualified for the ‘negative’ hif-1α
expression group, 25 patients (33%) for the ‘moderate’
hif-1α expression group and 18 patients (23%) qualified
for the ‘intense’ hif-1α expression group. Three patterns of
nuclear staining were encountered: focal expression, at
the rim of a necrotic area (Fig. 1a,b) or with the most
intense reaction occurring distal to the closest vessels
(Fig. 1c,d); or diffuse expression, which was independent
of vessel proximity (Fig. 1e,f). In most patients, there was
no exclusivity for one or the other staining pattern.
The cross-tabulations for patient-related, tumor-related
and therapy-related parameters are summarized in Table 1.
There was no correlation with well-known prognostic
parameters, such as the T stage, the grade or the number
of positive lymph nodes. A statistically significant
association existed only between hif-1α expression and
progesterone receptor expression (P = 0.006).
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Figure 1
Immunohistochemical staining on consecutive sections for (a), (c) and
(e) CD31 and (b), (d) and (f) hypoxia-inducible factor 1 alpha (hif-1α)
in human breast cancer. Classical hif-1α expression (b) at the border
of a necrotic region or (c) and (d) at a distance of 100–150 µm from
blood vessels. (e) and (f) Occasional diffuse hif-1α staining throughout
the entire tumor unpersuaded by the presence of capillary vessels.
Asterisk denotes necrotic area. Arrowheads point to capillaries.The actuarial 5-year DMFS, DFS and OS were 49%, 50%
and 59%, respectively. All deaths were judged to be
related to disseminated breast cancer. In the univariate
analysis, patients with higher hif-1α scores had a poorer
outcome. The relationship attained statistical significance
for DMFS and DFS if ‘hif-1α-positive’ tumors were
matched against the ‘negative’ group (P = 0.04 in each
case; Table 2). The Kaplan–Meier curves for DFS and for
hif-1α expression are shown in Fig. 2 for all patients.
The hif-1α expression and parameters with P < 0.1 in the
univariate analysis were included in a Cox regression
model. The multivariate analysis revealed the ‘number of
positive nodes’ to be significant for DMFS and DFS
(P = 0.02 each), whereas the ‘age’, the ‘estrogen receptor
status’ and the ‘hif-1α expression’ failed to obtain
statistical significance (Table 3). The only factor that was
found to be important for all three endpoints was the
‘advanced T stage’ (DMFS, relative risk = 3.16, P = 0.01;
DFS, relative risk = 2.57, P = 0.03; OS, relative risk =
3.03, P = 0.03).
Patients with T1/T2 tumors
Since an advanced tumor stage was found to be the most
important prognostic factor, we stratified the analyses
according to the T stage in order to ascertain whether
hif-1α had a prognostic impact in a subset of patients. No
significant impact was found for hif-1α expression in
Breast Cancer Research    Vol 6 No 3 Gruber et al.
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Table 1
Distribution of patient-related, tumor-related and therapy-related parameters and cross-tabulations with hypoxia-inducible factor
1 alpha (hif-1α α) expression
hif-1α
Parameter n (%) Negative Weak Strong P
Total 77 (100) 34 (44) 25 (33) 18 (23)
Age
< 50 years 23 (30) 8 (35) 10 (43) 5 (22) 0.38
> 50 years 54 (70) 26 (48) 15 (28) 13 (24)
T stage
T1/T2 55 (71) 26 (48) 16 (30) 13 (22) 0.57
T3/T4 22 (29) 8 (36) 9 (41) 5 (23)
Differentiation/grade
Moderate/G2 43 (56) 20 (46) 12 (28) 11 (26) 0.68
Poor/G3 32 (42) 12 (37) 13 (41) 7 (22)
Number of lymph nodes
1–3 27 (35) 14 (52) 8 (30) 5 (18) 0.58
≥ 4 50 (65) 20 (40) 17 (34) 13 (26)
Estrogen receptor
Positive 51 (66) 26 (51) 14 (27) 11 (22) 0.23
Negative 26 (34) 8 (31) 11 (42) 7 (27)
Progesterone receptor
Positive 41 (53) 25 (61) 9 (22) 7 (17) 0.006
Negative 36 (47) 9 (25) 16 (44) 11 (31)
Hormonotherapy
Yes 62 (81) 27(43) 19(31) 16(26) 0.56
No 15 (19) 7(47) 6(40) 2(13)
Chemotherapy
Yes 64 (83) 25(39) 23(36) 16(25) 0.13
No 13 (17) 9(69) 2(15) 2(15)patients with T3/T4 tumors (for DFS, P = 0.66; for DMFS,
P = 0.38; for OS, P = 0.16).
We then restricted the survival analysis to 55 patients with
T1/T2 tumors. The univariate analysis for DFS revealed the
‘number of positive nodes’ (P = 0.002) and the ‘hif-1α
expression’ (‘negative’ versus ‘moderate’ versus ‘intense’,
P = 0.028) as significant (Fig. 3). ‘Hormonal treatment’
was of borderline significance (P = 0.09). For DMFS, the
‘number of positive nodes’ (P = 0.002) and the ‘hif-1α
expression’ (‘negative’ versus ‘moderate’ versus ‘intense’,
P = 0.016) were significant. The ‘number of positive nodes’
was the only significant parameter for OS (P = 0.02).
A multivariate analysis including the aforementioned
parameters was performed for DMFS and DFS. Beside
the ‘number of positive nodes’, the ‘hif-1α expression’ was
significant for both DMFS (relative risk = 7.12, P = 0.01)
and DFS (relative risk = 7.04, P = 0.01), whereas ‘hormonal
treatment’ did not attain significance in patients with
T1/T2 tumors.
Discussion
Findings over the past few years indicate that genetically
modified cells [11] with an enhanced metastatic potential
[12] and those with diminished apoptosis [13] selectively
survive under hypoxic conditions, and that hypoxia may be
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Table 2
Univariate survival analysis (log-rank tests) of patient-related, tumor-related and therapy-related parameters
Distant metastasis-free  Disease-free  Overall 
Parameter survival P survival P survival P
Actuarial 5-year data (standard deviation) 49 (± 9) 50 (± 10) 59 (± 9)
Age
< 50 years 37 (± 15) 43 (± 14) 38 (± 16)
> 50 years 52 (± 12) 0.09 51 (± 12) 0.09 69 (± 10) 0.06
T stage
T1/T2 66 (± 9) 68 (± 8) 75 (± 9)
T3/T4 16 (± 13) 0.001 16 (± 13) 0.003 26 (± 15) 0.01
Differentiation/grade
Moderate/G2 54 (± 12) 58 (± 11) 49 (± 15)
Poor/G3 42 ± 15) 0.40 42 (± 15) 0.52 67 (± 12) 0.84
Number of positive lymph nodes
1–3 64 (± 20) 60 (± 21) 80 (± 15)
≥ 4 41 (± 10) 0.005 43 (± 10) 0.004 50 (± 11) 0.03
Estrogen receptor
Positive 57 (± 14) 58 (± 14) 63 (± 13)
Negative 37 (± 12) 0.04 36 (± 12) 0.03 52 (± 13) 0.14
Progesterone receptors
Positive 47 (± 20) 50 (± 21) 56 (± 16)
Negative 46 (± 10) 0.22 46 (± 11) 0.21 60 (± 12) 0.83
hif-1α expression
Intense 38 (± 15) 38 (± 15) 53 (± 17)
Moderate 48 (± 14) 50 (± 13) 50 (± 22)
No 56 (± 16) 0.12 58 (± 16) 0.13 66 (± 13) 0.46
hif-1α expression
Yes 43 (± 10) 44 (± 10) 55 (± 13)
No 56 (± 16) 0.04 58 (± 16) 0.04 66 (± 13) 0.21
hif-1α, hypoxia-inducible factor 1 alpha.a major parameter governing this selection. Once
equipped with the possibilities for survival under adverse
microenvironmental conditions, tumor cells are probably
also more resistant to cytotoxic therapies. This is
especially true for radiotherapy, but it might also be
important for pharmacotherapy with drugs such as
cyclophosphamide, adriamycin or 5-FU [14], which are
often used in the adjuvant treatment of breast cancer.
Malignant breast tumors are known to contain
heterogeneously distributed hypoxic areas with a median
oxygen tension of 23–28 mmHg, which is well below that
for normal breast tissue [15–17]. In only one study
involving cervical cancer have oxygen tension measure-
ments been compared with hif-1α staining; a significant
correlation was found to exist [5]. As previously described
[4,7], staining for hif-1α reflects two different expression
patterns. The first depends on the distance from blood
vessels, and on the proximity of necrotic regions, which
may accord with a decrease in oxygen concentration. The
other expression pattern is manifested as a diffuse
immunoreactivity throughout the entire tumor, indicating
that hif-1α expression can be influenced by factors other
than hypoxia. Indeed, growth factors and their receptors,
as well as the activation of other oncogenic signal
transduction pathways, may play a crucial role in the
Breast Cancer Research    Vol 6 No 3 Gruber et al.
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Figure 2
Disease-free survival (DFS) of 77 patients with high-risk breast cancer,
as a function of ‘negative’ versus ‘moderate’ versus ‘intense’ hypoxia-
inducible factor (hif) 1 alpha expression.
Figure 3
Disease-free survival (DFS) of 55 patients with T1/T2 breast cancer as
a function of ‘negative’ versus ‘moderate’ versus ‘intense’ hypoxia-
inducible factor (hif) 1 alpha expression.
Table 3
Multivariate survival analyses (Cox regression model) in node-positive breast cancer (n = 77)
Distant metastasis-free survival Disease-free survival Overall survival
Relative risk  Relative risk  Relative risk 
P (95% confidence interval) P (95% confidence interval) P (95% confidence interval)
Age
> 50 years versus < 50 years 0.14 0.50 (0.20–1.26) 0.20 0.56 (0.23–1.36) 0.13 0.43 (0.15–1.29)
T stage
T3/T4 versus T1/T2 0.01 3.16 (1.32–7.58) 0.03 2.57 (1.08–6.11) 0.03 3.03 (1.08–8.51)
Estrogen receptor
Positive versus negative 0.32 0.64 (0.26–1.56) 0.18 0.54 (0.22–1.33) –
Number of positive lymph nodes
4+ versus 1–3 0.02 4.06 (1.17–14.01) 0.02 4.42 (1.28–15.32) 0.16 3.00 (0.64–13.97)
hif-1α expression
Yes versus no 0.18 1.94 (0.73–5.17) 0.30 1.68 (0.62–4.47) 0.09 2.66 (0.83–8.51)
hif-1α, hypoxia-inducible factor 1 alpha.upregulation of hif-1α expression irrespective of tumor
hypoxia [3].
An increasing body of evidence indicates that hif-1α
expression is inversely correlated with tumor control
and/or patient survival. This has been demonstrated to
date for oligodendroglioma [18] and for a broad range of
carcinomas at different sites, such as the endometrium
[19], the uterine cervix [20,21], the ovary [22], the
esophagus [23], the lung [24], the head and neck [10,25]
and the breast [8,9]. In contrast, other studies have
revealed either no correlation between hif-1α expression
and outcome [5,26] or an improved survival rate [27,28].
These conflicting results may be explained either by the
low number of patients, and/or the existence of factors
that do not attain statistical significance, or by the specific
sensitivity of tumor cells towards a certain therapy. Our
data point to another possibility; namely, patient selection.
There is no doubt that the risk of subclinical distant
metastases at the time of diagnosis parallels the T stage
and the N stage. At a certain point of tumor progression, a
biological marker will probably lose its prognostic value
relative to the prognosticators for a worse outcome
(namely, increased tumor size and lymph node meta-
stases), even if the marker was instrumental in tumor
development and the aggressiveness of the disease.
Only two reports deal with the prognostic impact of hif-1α
expression in breast cancer. Bos and colleagues [9]
reported on 81 node-negative patients and 69 node-
positive patients treated between 1985 and 1993. High
levels of hif-1α had a profound impact on OS and DFS in
the subgroup of patients with node-negative tumors, but
had no influence on those with node-positive tumors [9].
In this series 139 out of 150 patients had T1 or T2
tumors, locally advanced tumours having been excluded.
Schindl and colleagues’ study [8] involved only node-
positive patients, almost all of these having T1 or T2
tumors (192 of the 206 patients), and hif-1α expression
was highly significant.
The findings of Schindl and colleagues regarding T1 and
T2 tumours are in agreement with our results. On the
contrary, Bos and colleagues did not make the same
observation. The discrepancy might be explained by the
circumstance that only patients with node-positive disease
underwent systemic therapy in Schindl and colleagues’
series, which might have influenced the prognostic value
of hif-1α expression. No correlation was found to exist
between hif-1α expression and the most important factors
for outcome (namely, the T stage [8,9] and the N stage
[9]), which supports our findings. More T3 and T4 tumors
were included in our study than in the previous studies,
which is an important circumstance since hif-1α
expression differed significantly in the univariate analysis
but not in the multivariate analysis for DFS in the presence
of these T3/T4 tumors. After exclusion of T3/T4 tumors,
hif-1α expression was a significant and independent factor
for DFS. It would appear that, in advanced disease, the
upregulation of hif-1α as a prognostic marker is repressed
by other adaptive mechanisms.
In all other cases, the inhibition of hif-1α pathways
represents a promising approach to the counteraction of
tumor progression. Concomitant treatment with hif-1α
antisense agents and cytotoxic drugs, such as cisplatin,
etoposide and vincristine, has been shown to have a
synergistic effect in vitro [29]. More data are required,
however, to assess the probable consequences in a
clinical setting.
Conclusions
In the present study, hif-1α was expressed in the majority
of node-positive breast cancer patients. The presence of
this protein is predictive of a poor outcome, although its
impact is less evident than an advanced T stage or the
number of positive lymph nodes. In addition to the number
of positive lymph nodes, however, hif-1α expression status
offers the possibility of defining disease-free survival more
precisely than other patient-related or tumor-related
parameters in T1/T2 tumors.
On the basis of our findings, it would appear that novel
biological markers can lose their prognostic value in locally
advanced disease stages. Nevertheless, they might furnish
additional information to the TNM staging system in
subgroups of patients.
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